45
Urological Cancer Kieran Jefferson Consultant Urological Surgeon University Hospital, Coventry

Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Embed Size (px)

DESCRIPTION

Recommended Texts Urology – a handbook for medical students Brewster, Cranston et al Oxford Handbook of Urology Similar authors, more postgraduate

Citation preview

Page 1: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Urological Cancer

Kieran JeffersonConsultant Urological SurgeonUniversity Hospital, Coventry

Page 2: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Recommended Texts

• Urology – a handbook for medical students

– Brewster, Cranston et al

• Oxford Handbook of Urology

– Similar authors, more postgraduate

Page 3: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Two-week wait urology

• Haematuria – – frank/microscopic over 50 years old

• Raised PSA/abnormal DRE• Mass in body of testis• Renal mass on imaging/palpation• Any suspicious penile lesion

Page 4: Urological Cancer Kieran Jefferson Consultant Urological Surgeon
Page 5: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Haematuria

• Common, major challenge for urologists

• Visible haematuria 20% chance cancer

• Microscopic haematuria 5-10% chance

Page 6: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Causes of haematuria

• Infection• Benign prostatic hypertrophy• Malignancy

– bladder, kidney, ureter, prostate

• Stone – bladder, ureter, kidney

• Glomerulonephritis– IgA nephropathy

• Trauma

Page 7: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Management

• History and examination

• Investigations

• Treatment

Page 8: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

History

• Type, duration, associated LUTS or pain• Medication

– Anticoagulants– nephrotoxins

• Medical/surgical history– stone or previous surgery

• SHx– Smoking, chemical exposure, employment

Page 9: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Examination

• Stigmata of renal disease– Hypertension– Oedema

• Abdomino-pelvic masses/scars

Page 10: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Investigations• Ideally as part of ‘one-stop’ haematuria

clinic

• MSU dipstix, M,C&S, cytology• FBC, U&Es• Flexible cystoscopy• USS renal tract +/- or contrast CT

Page 11: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Treatment

• As per aetiology

Page 12: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Bladder cancer

• 4th commonest male/10th commonest female cancer

• Risk Factors– Age, sex– Smoking, exposure to benzene compounds– Drugs – phenacetin, cyclophosphamide

Page 13: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Bladder cancer subtypes

• Primary– Transitional cell carcinoma– Squamous cell carcinoma– Adenocarcinoma– Sarcoma

• Secondary

Page 14: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Presentation

• Symptoms/signs from primary or secondary tumours +/- paraneoplastic phenomena

• Haematuria, dysuria, frequency/urgency• Ureteric obstruction

Page 15: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Ureteric obstruction

Page 16: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Management• As for all cancers, dependent on stage

and grade of tumour and co-morbidities

• TCCs described as GxTy (grade/TNM stage)

• Can be either curative or palliative

Page 17: Urological Cancer Kieran Jefferson Consultant Urological Surgeon
Page 18: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Diagnosis/staging

• Clinical diagnosis usually made at flexi cysto

• TURBT (including VE or DRE) to establish tissue diagnosis, then Mitomycin

• If tissue stage pT2 or greater, staging CT chest/abdo/pelvis

Page 19: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Treatment

• Superficial TCC (pT<2)– TURBT followed by regular review flexi cystoscopy– Intravesical treatment with mitomycin or bCG if high grade or

multiply recurrent– Recurrent high grade disease merits consideration of

cystectomy

• Invasive TCC or other subtypes– Radical surgery or radiotherapy after neoadjuvant

chemotherapy if cure possible– Palliative surgery/radiotherapy/medical symptom control

Page 20: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Prognosis

• Superficial TCC – excellent unless high-grade

• Invasive TCC – approx 50% overall 5y/s

• Metastatic – extremely poor

Page 21: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Renal cell cancer

• UK 7000 cases; 3600 deaths/year • 3% all cancer• Mortality is NOT declining• >50% incidental findings on imaging• 30% present with metastases

Page 22: Urological Cancer Kieran Jefferson Consultant Urological Surgeon
Page 23: Urological Cancer Kieran Jefferson Consultant Urological Surgeon
Page 24: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Clinical Features

• Asymptomatic (>50%)• Haematuria• Flank Pain• Mass

• Metastatic/paraneoplastic

Page 25: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

• Anaemia (>30%)• Erythrocytosis (3%)• Cachexia• Hepatic dysfunction• Hormonal abnormalities• Hypercalcaemia

Paraneoplastic Syndromes

Page 26: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Metastases

• Lung• Bone• Liver• Brain

Page 27: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Management

• Dependent on stage, grade & co-morbidity!• Curative vs palliative

• Only curative option is surgery– Laparoscopic radical nephrectomy– Lap/open partial nephrectomy

• Palliation with TKIs and mTOR antagonists

Page 28: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Prognosis

• Good if resectable primary tumour

• Very poor for metastatic disease

Page 29: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Prostate cancer

• Commonest solid tumour in UK males• 35000 cases & 10000 deaths per year

• Risk factors• Age, male sex

• Significantly less common in oriental races

Page 30: Urological Cancer Kieran Jefferson Consultant Urological Surgeon
Page 31: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Pathology

• Adenocarcinoma is commonest form (95%+)

• Gleason Grading system• Sum of two commonest morphologies

Page 32: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Presentation

• Asymptomatic • raised PSA/opportunistic DRE

• LUTS, lymphoedema, PE/DVT, ureteric obstruction/ARF, haematuria, impotence

• Bone pain, anaemia, sclerotic bone on XR

Page 33: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Management• Dependent on stage, grade & co-morbidity!

• History & Examination

• PSA, U/Es, FBC• Truss-guided prostate biopsy• Isotope bone scan/MRI prostate

Page 34: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Selecting treatment• Not all tumours warrant treatment (morbidity

of treatment outweighs potential benefit to patient)

• Whitmore’s conundrum– ‘Is it possible that no treatable prostate cancer

requires treatment, but that all those requiring treatment are untreatable?’

Page 35: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Treatment options

• Curative (radical)– Radical prostatectomy (open, laparoscopic, robotic)– Radical external beam radiotherapy– Brachytherapy

• Palliative– Watchful waiting– Hormone ablation– Chemotherapy– Radiotherapy

Page 36: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

‘The Third Way’

• Active surveillance– Aims to select out patients who will do badly and defer radical

treatment until progression is imminent– Good evidence that rate of change of PSA correlates well with

aggressiveness of tumour– Only immediate side-effect is psychological

Page 37: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Testicular cancer

• Commonest solid tumour of young men

• Commoner in European populations

• Exceptionally good prognosis due to effective platinum-based chemotherapy

Page 38: Urological Cancer Kieran Jefferson Consultant Urological Surgeon
Page 39: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Pathology

• Germ cell tumours (95%)• Seminoma, teratoma

• Sertoli cell tumours• Leydig cell tumours• Lymphomas (older men)

Page 40: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Presentation

• Painless testicular lump• Pain from infarction/infection/trauma

• Symptomatic metastases• Retroperitoneal lymph nodes (varicocoele)• Lungs, bones

Page 41: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Management

• Dependent on stage, grade & co-morbidity!

• But• Almost all are potentially curable• Co-morbidity is uncommon in these men

Page 42: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Assessment• History & Examination

• Serum Tumour Markers• Αlpha-foetoprotein (AFP)• ß-human chorionic gonadotrophin (hCG)• Lactate dehydrogenase (LDH)

• Radical orchidectomy for histology followed by CT chest/abdo/pelvis

Page 43: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Oncological management• Most now get chemotherapy

• Platinum-based

• Some also radiotherapy and retroperitoneal lymph node dissection

• Vast majority are cured but need regular imaging and risk second Ca

Page 44: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Penile cancer• Rare (in UK)• Association with HPV subtypes (cf cervical

cancer)• Any suspicious lesion on glans or prepuce

warrants early referral if fails to respond to steroids

• Squamous tumours usually treated surgically, some role for radiotherapy/chemo

Page 45: Urological Cancer Kieran Jefferson Consultant Urological Surgeon

Any questions?